We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Regeneron’s COVID-19 Antibody Drug Cocktail Completely Blocks Coronavirus Infection in Animal Test

By HospiMedica International staff writers
Posted on 05 Aug 2020
Print article
Illustration
Illustration
Regeneron Pharmaceuticals, Inc.’s (Tarrytown, NY, USA) COVID-19 antibody drug combination has prevented as well as treated the disease in rhesus macaques and hamsters, raising hopes of the cocktail treatment working for humans as well.

In animal studies of the antibody treatment on a total of 36 rhesus macaques and 50 hamsters, the company found that the results matched or exceeded the effects recently observed in animal studies of vaccine candidates. In one study, the cocktail of two monoclonal antibodies was able to “almost completely block establishment of virus infection,” according to the company. In a second study involving animals infected with a much higher level of the virus, the company found that the cocktail treatment managed to minimize infection and the prophylactic effect was significantly reduced when the dose was lowered.

Regeneron also found that in infected animals treated with the antibodies, the virus was cleared faster than those administered a placebo. Additionally, the company did not find any signs of a higher viral load or worsening of pathology after treatment in the animals, indicating that the antibody drug combination was unlikely to worsen symptoms in humans as well. Thus, the data suggests that Regeneron’s antibody cocktail therapy could offer clinical benefits in prevention as well as treatment of COVID-19. The company has already initiated late-stage clinical trials in humans to assess the antibody treatment’s ability to prevent and treat COVID-19, and has entered into a contract with the US government as part of its Operation Warp Speed program to provide the US with the treatment if the trials succeed.

Related Links:
Regeneron Pharmaceuticals, Inc.

Gold Member
12-Channel ECG
CM1200B
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.